Dupilumab in pregnancy: no major safety signals found
NCT ID NCT04173442
First seen Mar 19, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study looked at the safety of using dupilumab during pregnancy in women with atopic dermatitis or asthma. Researchers compared pregnancy and infant outcomes between women who took dupilumab and those who did not. The goal was to see if the drug increased the risk of birth defects or other problems. The study enrolled 581 pregnant women in North America.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regeneron Research Site
La Jolla, California, 92093-0934, United States
Conditions
Explore the condition pages connected to this study.